Sign in
Active, not recruitingNo phase

Healing Opioid Misuse and Pain Through Engagement (HOPE) Trial

Key facts

Who runs it
University of New Mexico
Where
Albuquerque and Ann Arbor, United StatesSee the 2 sites
Trial code
Status
Active, not recruiting
People taking part
160 people, planned
Started
5 May 2023
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention (ACT + MBRP)
  • Enhance Usual Care (EUC)
Record updated
30 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Stabilized on a dose of buprenorphine for a period of at least 1 month. Buprenorphine stabilization will be defined as a consistent dose for at least 30 consecutive days
  • Willing to comply with all study procedures and be available for the duration of the study
  • Aged 18 years or older
  • Enrolled as a patient in one of the participating clinics
  • Presence of chronic pain for > 6 months in duration

Who cannot take part

  • Current or past diagnosis of schizophrenia, delusional disorder, psychotic or dissociative disorders
  • Have a substance use disorder requiring a higher level of care than outpatient treatment (e.g., severe alcohol use disorder requiring inpatient detoxification)
  • Unable to read English

Where in United States

  • University of New MexicoAlbuquerque, United States
  • University of MichiganAnn Arbor, United States

About the trial

What the trial wants to find out

This study is a multisite randomized clinical trial of a treatment designed to reduce pain interference while simultaneously addressing relapse prevention among individuals who have co-occurring chronic pain and Opioid Use Disorder (OUD). This study will recruit approximately 160 individuals who are currently being treated in clinics specializing in the physician management of OUD. To increase generalizability of study findings and increase internal validity of the physician management component of treatment, all participants will be stabilized on buprenorphine for OUD as part of their usual clinical care. Individuals will be randomized to either: (1) enhanced usual care or (2) the integrated ACT + MBRP treatment. The investigators hypothesize that: (1) the combination of ACT + MBRP in buprenorphine-prescribed patients with chronic pain will be more efficacious across primary and secondary outcome measures in comparison to Enhanced Usual Care and (2) examination of treatment mechanism data will indicate treatment-related changes that are consistent with the theoretical models of ACT+MBRP.

The 2 groups in the trial

  • ACT + MBRP InterventionTreatment being tested

    The ACT + MBRP group will follow a manualized clinical protocol. Treatment will include 12 weekly, virtual group-based sessions, each lasting 90 minutes. Group sizes will range from three to ten participants. All sessions will be audio recorded for fidelity. Over the course of the group meetings, participants identify areas of meaningful functioning that have been adversely impacted by pain, learn methods to enhance pain willingness in the service of these meaningful areas, and practice present-focused awareness skills. Group sessions include discussions of the impact of pain and distress avoidance, identifying alternatives to this avoidance and establishing plans for behavior change, demonstration and role-playing exercises, and homework assignments. Participants are provided with a treatment manual to help guide and inform practice outside of group sessions.

    Treatment: Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention (ACT + MBRP)

  • Enhanced Usual Care (EUC)Existing treatment, for comparison

    The Enhanced Usual Care (EUC) condition will supplement standard practices within the study sites related to chronic pain and OUD education. Participants randomized to the EUC condition will receive a brochure (in-person, via email, or via text message) with a list of chronic pain treatment resources, signs and management of opioid overdose including naloxone, and overdose prevention, and will encouraged to schedule an appointment with a clinical provider if they would like to discuss any current or past symptoms. In addition to receiving the brochure, EUC condition participants will meet with a therapist remotely for approximately 15 minutes for a descriptive overview of the brochure. In this session, the therapist will point out the resources in the brochure and read the helpful tips out loud to the participant. This session will be audio recorded for fidelity.

    Treatment: Enhance Usual Care (EUC)

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Integrative Treatment for Achieving Holistic Recovery From Comorbid Chronic Pain and Opioid Use Disorder
Record updated
30 October 2026